Funding Sources

Adult IA Adult Inflammatory Arthritis Guideline

Since inception in 2019, funding to support the development of the Adult Inflammatory Arthritis living guideline has been provided by:

2018–ongoing

ANZMUSC Clinical Trials Network

Core operational funding for guideline development and maintenance

2023–2027

NHMRC ANZMUSC Centre of Research Excellence

Continued funding through the second ANZMUSC CRE grant

2018–2022

NHMRC ANZMUSC Centre of Research Excellence

Initial CRE funding supporting guideline establishment

2022–2024

Victorian Government via ALEC

Australian Living Evidence Consortium funding

Until mid-2026

Cochrane Musculoskeletal

NHMRC Cochrane editorial base funding

2019–2022

Australian Department of Health VIP Program

Value in Prescribing bDMARDs Program Grant, awarded to the Targeted Therapies Alliance led by NPS MedicineWise

JIA Juvenile Idiopathic Arthritis Guideline

Since inception in 2020, funding to support the development of the JIA living guideline has been provided by:

2020–2023

Arthritis Australia Health Professional Education and Training Grant

GO ID: GO2794

2022–2026

Medical Research Future Fund (MRFF)

Chronic Musculoskeletal Conditions in Children and Adolescents Grant

2018–2022

NHMRC ANZMUSC Centre of Research Excellence

Initial CRE funding supporting guideline establishment

2023–2027

NHMRC ANZMUSC Centre of Research Excellence

Continued funding through the second ANZMUSC CRE grant

NHMRC Approval

Both guidelines have been approved by the National Health and Medical Research Council (NHMRC) under Section 14A of the National Health and Medical Research Council Act 1992.

Adult IA Adult Inflammatory Arthritis Guideline

3 September 2025
Version 5.0 approved by NHMRC Chief Executive Officer, Professor Steve Wesselingh. Comprises a further two recommendations.
9 July 2024
Version 4.0 approved by NHMRC Acting Chief Executive Officer. Comprises a further two recommendations.
27 July 2023
Version 3.0 approved by NHMRC Acting Chief Executive Officer, Prue Torrance. Comprises a further three recommendations.
5 August 2022
Version 2.0 approved by NHMRC CEO, Professor Kelso. Comprises a further six recommendations.
7 July 2021
Version 1.0 approved by the Acting Chief Executive Officer of the NHMRC. Comprises the first six recommendations.

JIA Juvenile Idiopathic Arthritis Guideline

3 September 2025
Version 3.0 approved by NHMRC Chief Executive Officer, Professor Steve Wesselingh. Comprises a further two recommendations (now 9 total).
8 December 2023
Version 2.0 approved by Chief Executive Officer of NHMRC, Professor Steve Wesselingh. Comprises a further four recommendations.
6 December 2022
Version 1.0 approved by the Acting Chief Executive Officer of the NHMRC. Comprises the first three recommendations.

In approving the guideline recommendations, NHMRC considers that they meet the NHMRC standard for clinical practice guidelines. Each approval is valid for a period of five years.

NHMRC is satisfied that the guideline recommendations are systematically derived, based on the identification and synthesis of the best available scientific evidence, and developed for health professionals practising in an Australian health care setting.

This publication reflects the views of the authors and not necessarily the views of the Australian Government.

How to Cite These Guidelines

Adult IA Adult Inflammatory Arthritis Guideline
APA Style
Australia and New Zealand Musculoskeletal Clinical Trials Network. An Australian Living Guideline for the Pharmacological Management of Inflammatory Arthritis. https://livingguidelines.org/adult/. Accessed [insert date].
Vancouver Style
Australia and New Zealand Musculoskeletal Clinical Trials Network. An Australian Living Guideline for the Pharmacological Management of Inflammatory Arthritis. Available from: https://livingguidelines.org/adult/. Accessed [insert date].
JIA Juvenile Idiopathic Arthritis Guideline
APA Style
Australia and New Zealand Musculoskeletal Clinical Trials Network. An Australian Living Guideline for the Management of Juvenile Idiopathic Arthritis. https://livingguidelines.org/jia/. Accessed [insert date].
Vancouver Style
Australia and New Zealand Musculoskeletal Clinical Trials Network. An Australian Living Guideline for the Management of Juvenile Idiopathic Arthritis. Available from: https://livingguidelines.org/jia/. Accessed [insert date].

Copyright

This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction.

Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given the specific written permission from ANZMUSC.

Requests and inquiries concerning reproduction and rights should be sent to vanessa.glennon@monash.edu.

Disclaimer

These clinical guidelines have been informed by the highest quality evidence available at the time of compilation. Accordingly, the parties involved in the development of these guidelines shall have no liability to any users of the information contained in this publication for any loss or damage, cost or expense incurred or arising from reliance on the information contained in this publication.